| Schedule of revenue from contract with customer and other income by nature |
| | | | | | | | | | | For the three months | | For the six months | | | ended June 30, | | ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Collaborative research funding | | — | | 115,277 | | — | | 348,757 | Fair value of services received at zero cost from Neurosterix Group | | 34,505 | | — | | 105,560 | | — | Other service income | | 1,870 | | — | | 1,870 | | 1,430 | Total | | 36,375 | | 115,277 | | 107,430 | | 350,187 |
|
| Schedule of revenue from contract with customer and other income by major counterparties |
| | | | | | | | | | | For the three months | | For the six months | | | ended June 30, | | ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Indivior PLC | | — | | 115,277 | | — | | 348,757 | Neurosterix Group | | 34,505 | | — | | 105,560 | | — | Other counterparties | | 1,870 | | — | | 1,870 | | 1,430 | Total | | 36,375 | | 115,277 | | 107,430 | | 350,187 |
|
| Schedule of geographical areas |
| | | | | | | June 30, | | December 31, | | | 2025 | | 2024 | Switzerland | | 5,848,099 | | 7,136,602 | France | | 336 | | 338 | Total | | 5,848,435 | | 7,136,940 |
| | | | | | | | | | | For the three months | | For the six months | | | ended June 30, | | ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Switzerland | | 765,310 | | 1,010,390 | | 1,439,158 | | 2,031,464 | United States of America | | 2,840 | | 2,371 | | 5,155 | | 4,017 | France | | 1,123 | | 1,832 | | 2,277 | | 2,114 | Total operating costs (note 18) | | 769,273 | | 1,014,593 | | 1,446,590 | | 2,037,595 |
|